4.4 Article

Design, Synthesis, and Sustained-Release Property of 1,3-Cyclic Propanyl Phosphate Ester of 18β-Glycyrrhetinic Acid

期刊

CHEMICAL BIOLOGY & DRUG DESIGN
卷 77, 期 3, 页码 206-211

出版社

WILEY-BLACKWELL
DOI: 10.1111/j.1747-0285.2010.01077.x

关键词

18 beta-glycyrrhetinic acid; prodrug; sustained-release properties; the mean residence time

资金

  1. Ministry of Science and Technology of the People's Republic of China [2008DFA31040]

向作者/读者索取更多资源

A new class of potential prodrugs, 1,3-cyclic propanyl phosphate esters of 18 beta-glycyrrhetic acid, was designed and synthesized through the key reaction of 18 beta-glycyrrhetic acid with 1,3-cyclic propanyl phosphate ester catalysed by lithium diisopropylamide. The sustained-release properties of 1,3-cyclic propanyl phosphate esters of 18 beta-glycyrrhetic acid in vivo were also investigated. The animal experiments showed that 18 beta-glycyrrhetic acid was released from 1,3-cyclic propanyl phosphate esters of 18 beta-glycyrrhetic acid at a steady rate in rats and the plasma concentrations of 18 beta-glycyrrhetic acid were nearly stable. The result indicated that 1,3-cyclic propanyl phosphate esters of 18 beta-glycyrrhetic acid have sustained-release properties to avoid the quick metabolism of 18 beta-glycyrrhetic acid. These prodrugs are highlighted as a promising new strategy to improve 18 beta-glycyrrhetic acid metabolism.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
Article Biochemistry & Molecular Biology

Dihydropyrimidine derivatives as MDM2 inhibitors

Ali Mehri, Karim Mahnam, Hajar Sirous, Mahmoud Aghaei, Leila Rafiei, Mahboubeh Rostami

Summary: One potential approach for tumor therapy is inhibiting the binding between MDM2 and p53 to reactivate p53 in tumor cells. In this study, Monastrol derivatives were designed as MDM2 inhibitors and evaluated for their cytotoxicity on cancer cells. Compound 5d showed the best inhibitory results in silico and in vitro experiments. These findings suggest that Monastrol derivatives have the potential to be candidates for MDM2 inhibition.

CHEMICAL BIOLOGY & DRUG DESIGN (2024)